Sulfonylureas (SUs) were the first class of oral antidiabetic agents and remain among the most widely prescribed worldwide, particularly in lower-resource settings, because of their low cost, well-characterized efficacy, and decades of clinical experience. Their mechanism of action is a direct pharmacological extension of the physiological glucose-sensing pathway in pancreatic beta cells: they close the ATP (adenosine triphosphate)-sensitive potassium channel (KATP channel) by binding to its regulatory SUR1 (sulfonylurea receptor 1) subunit, mimicking the effect of a high ATP/ADP (adenosine diphosphate) ratio and thereby triggering insulin secretion independently of ambient glucose concentration. This glucose-independent secretion is both the source of their efficacy and the mechanistic basis of their primary risk: hypoglycemia.
The KATP channel is a hetero-octameric complex assembled from four Kir6.2 (inward-rectifier potassium channel 6.2) pore-forming subunits and four SUR1 regulatory subunits, each SUR1 containing two cytoplasmic nucleotide-binding domains (NBD1 and NBD2) that sense the intracellular ATP/ADP ratio. Under basal (fasting) conditions, Mg-ADP occupancy of NBD2 stabilizes the channel in its open state, maintaining the beta cell membrane at its resting potential of approximately -70 mV and suppressing insulin secretion. When glucose metabolism raises the ATP/ADP ratio, ATP displaces Mg-ADP from NBD2, shifting the KATP channel conformational equilibrium toward the closed state, depolarizing the membrane, and initiating calcium-dependent exocytosis. Sulfonylureas bind to the cytoplasmic face of SUR1 at a distinct drug-binding site that allosterically stabilizes the channel in its closed state regardless of the nucleotide ratio, thereby triggering insulin secretion without any requirement for elevated intracellular glucose metabolism. This mechanism is preserved in patients with defective glucose sensing or impaired glycolysis but intact SUR1 expression, explaining why sulfonylureas retain partial efficacy in advanced type 2 diabetes mellitus (T2DM) even when first-phase insulin secretion is lost.1
Sulfonylureas are divided into first-generation agents (tolbutamide, chlorpropamide, tolazamide) and second-generation agents (glipizide, glyburide, glimepiride). First-generation agents are now rarely used in high-income countries due to unfavorable pharmacokinetic profiles and significant drug interaction risks. Second-generation agents have substantially higher binding affinity for SUR1, allowing effective doses in the milligram rather than gram range, and have largely supplanted first-generation agents in clinical practice. Glipizide undergoes extensive hepatic metabolism via CYP2C9 (cytochrome P450 2C9) to inactive metabolites and is renally excreted; its relatively short duration of action (12 to 24 hours) and hepatic inactivation make it the preferred sulfonylurea in patients with CKD (chronic kidney disease), as it does not accumulate in renal failure. Glyburide (glibenclamide) is metabolized in the liver to weakly active metabolites that are renally excreted; these metabolites accumulate in CKD, significantly extending duration of action and substantially increasing hypoglycemia risk, making glyburide the most dangerous sulfonylurea in patients with reduced renal function and the agent most consistently avoided in this population. Glimepiride is metabolized by CYP2C9 to an active metabolite (M1) with approximately one-third the potency of glimepiride, followed by further reduction to an inactive M2 (second-phase metabolite) metabolite; the primary and M1 metabolites are renally excreted, requiring dose reduction in CKD, though glimepiride is generally better tolerated in moderate renal impairment than glyburide.1
The ADME (absorption, distribution, metabolism, and excretion) profile of sulfonylureas is broadly similar across the class. All are well absorbed orally (bioavailability greater than 80 percent), reach peak plasma concentrations within 1 to 4 hours of dosing, and are highly protein-bound (greater than 90 percent to albumin), which creates a clinically significant drug interaction with other highly protein-bound drugs that can displace sulfonylureas from albumin binding sites and transiently increase free drug concentrations. The volume of distribution is small (approximately 0.1 to 0.15 L/kg), consistent with the predominantly vascular distribution of a highly protein-bound drug. Plasma half-lives range from approximately 5 to 8 hours for glipizide to 10 to 16 hours for glimepiride, but the pharmacodynamic duration of glucose lowering typically exceeds the plasma half-life because insulin secretion persists beyond drug clearance when the secretory threshold has been triggered. All sulfonylureas should be taken before meals to allow drug absorption to coincide with postprandial glucose excursion, reducing the risk of pre-meal hypoglycemia.3
Hypoglycemia is the principal adverse effect of sulfonylureas and the primary clinical concern limiting their use, particularly in older adults and in patients with CKD or erratic food intake. Unlike insulin-induced hypoglycemia, where the glucose-lowering effect is tied to injected dose and timing, sulfonylurea-induced hypoglycemia can be prolonged (lasting 12 to 24 hours for long-acting agents) and recurrent without additional drug exposure, because the residual drug in plasma continues to stimulate insulin secretion as the patient recovers and glucose normalizes. This makes hospital admission for observation appropriate after severe sulfonylurea-induced hypoglycemia, with continuous IV (intravenous) dextrose infusion to maintain euglycemia until drug clearance is complete. The risk of hypoglycemia is substantially higher with glyburide than with glipizide or glimepiride in both observational and randomized data, consistent with the longer pharmacodynamic duration of glyburide and its accumulation in renal impairment.2 Among second-generation agents, glimepiride has a modest insulin-sparing effect at lower glucose levels due to differential binding characteristics at SUR1, producing slightly lower hypoglycemia rates than glyburide at equivalent glycated hemoglobin (HbA1c) reductions.3
Glyburide (glibenclamide) is specifically contraindicated in significant renal impairment (estimated glomerular filtration rate, eGFR, below 30 mL/min/1.73m2 and should be used cautiously at eGFR 30 to 60 mL/min/1.73m2) because its weakly active metabolites accumulate with declining renal function, dramatically prolonging insulin secretion and producing severe, prolonged hypoglycemia. The risk is compounded in older adults in whom renal function may decline acutely with dehydration or intercurrent illness. Glipizide, which is inactivated to non-pharmacologically active metabolites by CYP2C9, is the preferred sulfonylurea in CKD stages 3 to 4 when a secretagogue is clinically required. All sulfonylureas should be used with extreme caution in CKD stage 4 or worse.
Weight gain of approximately 2 to 4 kg over 6 to 12 months of sulfonylurea therapy is a predictable consequence of the insulin secretagogue mechanism, driven by the same pathway as insulin-associated weight gain: reversal of glycosuria, enhanced anabolic effect of elevated insulin, and defensive carbohydrate consumption in response to hypoglycemia episodes. This weight gain worsens insulin resistance in T2DM, driving a cycle of escalating secretagogue requirements that accelerates beta cell exhaustion. The concern that chronic KATP channel closure in non-beta cell tissues (cardiac myocytes express SUR2A (sulfonylurea receptor 2A)-containing KATP channels that serve an ischemic preconditioning function) might worsen cardiovascular outcomes with sulfonylureas was raised by the UGDP (University Group Diabetes Program) study with tolbutamide in the 1970s and has remained a topic of debate. Observational data suggest a modest increase in cardiovascular mortality with glyburide compared with other oral agents, but this signal is confounded by channeling bias, and large prospective trials have not definitively established a cardiovascular harm signal for second-generation sulfonylureas. Nonetheless, in patients with established cardiovascular disease or high cardiovascular risk, preferential use of agents with demonstrated cardiovascular benefit (GLP-1 (glucagon-like peptide-1) receptor agonists, SGLT-2 (sodium-glucose cotransporter-2) inhibitors) over sulfonylureas is recommended by current guidelines.3
Meglitinides (also called glinides or non-sulfonylurea secretagogues) share the same ultimate pharmacological target as sulfonylureas, the KATP (ATP-sensitive potassium) channel in pancreatic beta cells, but bind at a distinct site on SUR1 (sulfonylurea receptor 1) with markedly faster association and dissociation kinetics. This rapid on-off binding profile produces a short-duration insulin secretory burst timed to meal ingestion, designed to replicate physiological first-phase insulin release more closely than sulfonylureas and to carry a lower risk of interprandial and nocturnal hypoglycemia by allowing recovery of KATP channel openings between meals.4
Repaglinide is a benzoic acid derivative that binds to a distinct receptor site on SUR1 from sulfonylureas, though both sites are located on the same subunit and both produce KATP channel closure by allosteric stabilization of the closed state. The repaglinide binding site (the benzamido site) has faster association and dissociation kinetics than the sulfonylurea binding site (the sulfonylurea site), translating into a shorter duration of action and more complete channel reopening between doses. Repaglinide is rapidly absorbed orally, reaching peak plasma concentration within 1 hour of administration. It is extensively metabolized by CYP3A4 (cytochrome P450 3A4) and CYP2C8 (cytochrome P450 2C8) to inactive metabolites that are eliminated primarily in bile and feces, with less than 10 percent renal excretion of unchanged drug. This predominantly hepatic/biliary elimination route means that repaglinide can be used in patients with CKD (chronic kidney disease) without dose accumulation due to renal impairment, a significant pharmacokinetic advantage over sulfonylureas in this population. However, significant drug interactions arise from CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and CYP2C8 inhibitors (e.g., gemfibrozil), which markedly increase repaglinide exposure; gemfibrozil co-administration raises repaglinide AUC (area under the curve) by approximately eight-fold and is a contraindicated combination due to severe hypoglycemia risk.12
Nateglinide is a phenylalanine derivative that also closes beta cell KATP channels but has an even faster dissociation rate from SUR1 than repaglinide, producing a shorter and lower-amplitude insulin secretory response. Its glucose-lowering efficacy is accordingly more modest: nateglinide produces approximately 0.5 to 0.8 percent HbA1c reduction as monotherapy, compared with 1.0 to 1.5 percent for repaglinide and 1.0 to 2.0 percent for sulfonylureas, reflecting the trade-off between insulin secretory amplitude and reduced hypoglycemia risk. Nateglinide is rapidly absorbed (peak at 1 hour), has a plasma half-life of approximately 1.5 hours, and is metabolized by CYP2C9 (cytochrome P450 2C9) to metabolites that retain some activity, with renal excretion of metabolites. The speed of nateglinide kinetics requires administration immediately before each meal (within 30 minutes); if a meal is skipped, the dose must be omitted to avoid hypoglycemia. Nateglinide is particularly suited to patients with primarily postprandial hyperglycemia and relatively preserved fasting glucose, where its narrow targeting of meal-related insulin output is pharmacologically matched to the glycemic abnormality.12
Meglitinides offer advantages over sulfonylureas in specific clinical contexts: (1) patients with irregular meal schedules who cannot reliably anticipate mealtimes, since the dose-per-meal design avoids the fixed-timing constraint of sulfonylureas; (2) patients with CKD in whom sulfonylurea metabolite accumulation is a concern, given repaglinide's predominantly biliary elimination; (3) patients with predominantly postprandial hyperglycemia, in whom short-acting prandial coverage is pharmacologically appropriate; (4) patients with a history of severe prolonged sulfonylurea-induced hypoglycemia who require a secretagogue. Disadvantages include the requirement for multiple daily doses (with each meal), higher cost than generic sulfonylureas, and the important gemfibrozil interaction for repaglinide. For most patients with T2DM requiring a secretagogue, second-generation sulfonylureas remain the first choice due to lower cost and established long-term data.
Both meglitinides are administered before each main meal, typically two to three times daily, and both produce weight gain through the same mechanisms as sulfonylureas: enhanced insulin secretion drives anabolic effects and may precipitate defensive carbohydrate intake with hypoglycemia. The weight gain with meglitinides is generally modest, approximately 1 to 3 kg, and somewhat less than with sulfonylureas in comparative trials, consistent with the lower interprandial insulin levels. The cardiovascular safety of meglitinides has not been evaluated in large dedicated outcomes trials analogous to those conducted for other antidiabetic drug classes, and their use is limited primarily to patients in whom sulfonylurea use is inappropriate or in combination regimens where short-acting prandial coverage is the specific therapeutic goal. Both agents require dose adjustment in severe hepatic impairment, as the liver is the primary metabolic organ for both, and both are contraindicated in T1DM (type 1 diabetes mellitus) where their insulin secretagogue mechanism is pharmacologically ineffective in the absence of functional beta cells.12
Metformin is a biguanide derived from galegine, a natural product of Galega officinalis (French lilac, goat's rue), and has been in continuous clinical use since the late 1950s. It remains the most widely prescribed oral antidiabetic agent globally and the universal first-line pharmacological therapy for T2DM (type 2 diabetes mellitus) in all major guidelines, supported by a unique combination of efficacy, metabolic benefits, cardiovascular outcome data, favorable adverse effect profile, and low cost. Its mechanism of action is complex, multilevel, and still not fully elucidated, operating through at least four distinct but interdependent pathways that collectively reduce hepatic glucose output and improve peripheral insulin sensitivity.
The primary and best-characterized mechanism of metformin action is inhibition of mitochondrial complex I (NADH (nicotinamide adenine dinucleotide, reduced form):ubiquinone oxidoreductase, the first enzyme of the electron transport chain) in hepatocytes. Metformin enters hepatocytes via OCT1 (organic cation transporter 1) on the sinusoidal membrane, where it accumulates intracellularly at concentrations substantially higher than in plasma due to its cationic charge and mitochondrial membrane potential-driven uptake into the mitochondrial matrix. Within mitochondria, metformin inhibits complex I, reducing the rate of electron transfer from NADH (nicotinamide adenine dinucleotide, reduced form) to ubiquinone and thereby decreasing the rate of oxidative phosphorylation and ATP (adenosine triphosphate) synthesis. The resulting modest rise in the AMP (adenosine monophosphate)/ATP ratio within hepatocytes activates AMPK (AMP-activated protein kinase, the cellular energy sensor), a serine-threonine kinase that phosphorylates and inactivates ACC (acetyl-CoA carboxylase), reducing malonyl-CoA production and relieving CPT1 (carnitine palmitoyltransferase 1) inhibition, thereby increasing fatty acid oxidation. AMPK also phosphorylates and inactivates TORC2 (transducer of regulated CREB activity 2), the essential co-activator of CREB (cAMP response element-binding protein)-dependent transcription of PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase), the rate-limiting enzymes of hepatic gluconeogenesis. The net result is a substantial reduction in hepatic glucose production, the dominant glycemic effect of metformin and the primary explanation for its preferential lowering of fasting plasma glucose.5
A second mechanism, increasingly recognized as significant, operates independently of AMPK. Metformin's complex I inhibition reduces mitochondrial NADH oxidation, raising the cytosolic NADH-to-NAD+ (nicotinamide adenine dinucleotide oxidized form) ratio and thereby inhibiting the conversion of lactate and glycerol to gluconeogenic substrates. Because hepatic gluconeogenesis from lactate (via lactate dehydrogenase, requiring NAD+) and from glycerol (via glycerol-3-phosphate dehydrogenase, also requiring NAD+) depends on adequate cytosolic NAD+ availability, the elevated NADH-to-NAD+ ratio directly limits substrate flux into the gluconeogenic pathway. This AMPK-independent gluconeogenesis suppression was demonstrated in a landmark study using isotopic glucose tracer infusions in mice with liver-specific AMPK deletion, which showed equivalent metformin-mediated fasting glucose reduction in AMPK-null and wild-type animals. The clinical implication is that metformin's hepatic effect is at least partly resistant to AMPK pathway disruptions that might develop in insulin-resistant states.6
Beyond hepatic effects, metformin has significant actions in the gastrointestinal tract that contribute to its glucose-lowering and metabolic effects. At therapeutic concentrations, metformin inhibits intestinal glucose absorption through effects on mucosal glucose transporters including SGLT1 (sodium-glucose cotransporter 1) and GLUT2 (glucose transporter 2) in enterocytes, reducing postprandial glucose excursions by slowing the rate of glucose entry into the portal circulation. Metformin also stimulates GLP-1 (glucagon-like peptide-1) secretion from enteroendocrine L cells in the distal ileum through multiple mechanisms: increased delivery of unabsorbed glucose to the distal gut, where it stimulates L cell secretion; direct GLP-1 secretagogue effects via bile acid pathway modulation; and alterations in gut microbiome composition that promote GLP-1-releasing short-chain fatty acid production. Metformin preferentially alters the gut microbiome toward Akkermansia muciniphila enrichment and Escherichia/Shigella reduction, and several studies have demonstrated that germ-free or antibiotic-treated animals show attenuated metformin responses, suggesting the gut microbiome is a meaningful contributor to metformin pharmacology.7 The gastrointestinal adverse effects of metformin (nausea, diarrhea, abdominal discomfort) are mechanistically linked to these intestinal actions: high luminal metformin concentrations in the proximal gut disrupt enterocyte mitochondrial function, alter gut motility, and may directly affect the enteric nervous system.8
The ADME (absorption, distribution, metabolism, and excretion) profile of metformin is distinctive among oral antidiabetics and directly relevant to its clinical use and safety. Metformin is a hydrophilic, highly ionized molecule at physiological pH that is not metabolized and is excreted unchanged by the kidneys via glomerular filtration and active tubular secretion through OCT2 (organic cation transporter 2) on the basolateral membrane of proximal tubular cells and MATE1/MATE2-K (multidrug and toxin extrusion proteins) on the luminal membrane. Oral bioavailability from immediate-release tablets is approximately 50 to 60 percent, with absorption primarily in the upper small intestine; the remainder passes into the lower gut where it exerts its intestinal effects and is eliminated in feces.
Peak plasma concentrations occur at 2 to 3 hours for immediate-release formulations and at 4 to 8 hours for XR (extended-release) formulations. The XR formulation was developed primarily to reduce gastrointestinal adverse effects by slowing luminal drug release and reducing peak proximal intestinal drug concentrations; clinical trials demonstrate approximately 30 to 40 percent lower rates of gastrointestinal intolerance with metformin XR compared with immediate-release at equivalent doses. The plasma half-life is approximately 4 to 8 hours, but the effective pharmacodynamic duration exceeds this because of continued intestinal and tissue drug effects. Because metformin is entirely dependent on renal clearance, renal impairment causes proportional drug and lactate accumulation, which is the mechanistic basis of the rare but potentially fatal metformin-associated lactic acidosis (MALA).8
OCT1 (SLC22A1) genetic variants significantly affect hepatic metformin accumulation and clinical response. Loss-of-function polymorphisms in OCT1 (particularly rs12208357, rs34130495, and rs72552763) reduce hepatic uptake of metformin, attenuating its inhibition of hepatic gluconeogenesis and blunting the HbA1c-lowering response. Patients carrying two reduced-function OCT1 alleles may have substantially diminished glycemic response to metformin despite adequate plasma concentrations. OCT1 variants are more common in European populations (carrier frequency 10 to 20 percent for individual variants) than in East Asian populations. While pharmacogenomic testing for OCT1 variants before metformin initiation is not yet standard clinical practice, this biology explains a meaningful portion of the clinical variability in metformin response and supports the concept of personalized antidiabetic prescribing as pharmacogenomic data become more accessible.
Metformin stands apart from other antidiabetic agents in having prospective randomized trial data demonstrating reduction in cardiovascular mortality and all-cause mortality that is independent of its glycemic effect, established over 25 years of follow-up. This evidence base, combined with weight neutrality or modest weight reduction, absence of hypoglycemia risk, and low cost, explains its universal first-line status and has prompted investigation of metformin in non-diabetic cardiometabolic conditions, polycystic ovary syndrome (PCOS), cancer prevention, and aging biology.
The foundational clinical evidence for metformin comes from the UKPDS (United Kingdom Prospective Diabetes Study), a landmark randomized controlled trial enrolling 5,102 patients with newly diagnosed T2DM (type 2 diabetes mellitus) between 1977 and 1991. In the overweight T2DM subgroup (n=753) randomized to metformin versus conventional dietary therapy, metformin produced a 36 percent reduction in all-cause mortality (p=0.011), a 39 percent reduction in myocardial infarction risk, and a 32 percent reduction in any diabetes-related endpoint, benefits that exceeded those achieved by sulfonylurea or insulin therapy in the broader UKPDS cohort despite similar glycemic control as measured by HbA1c. The 10-year post-trial follow-up (UKPDS 80) demonstrated that this mortality benefit was sustained and even strengthened over time in the metformin group, a legacy effect not observed for sulfonylurea-treated patients, suggesting metabolic or vascular effects of metformin that persist beyond the period of drug treatment and are not fully explained by blood glucose lowering alone.15 These findings established metformin as the unique oral antidiabetic agent with mortality benefit independent of glycemic control.9
The principal safety concern associated with metformin is lactic acidosis, a life-threatening metabolic emergency with mortality of approximately 50 percent in case series. Metformin inhibits hepatic and renal lactate clearance by reducing complex I activity in these tissues, raising circulating lactate concentrations modestly even at therapeutic doses. Lactic acidosis occurs when this lactate accumulation becomes severe, typically in clinical contexts where metformin clearance is markedly reduced (severe renal impairment), lactate production is increased (sepsis, shock, respiratory failure, hepatic failure), or both simultaneously. The absolute incidence of metformin-associated lactic acidosis (MALA) at appropriate doses in renally normal patients is extremely low, estimated at 3 to 10 cases per 100,000 patient-years in large pharmacoepidemiology studies, comparable to or lower than lactic acidosis rates in matched T2DM patients not on metformin, leading some authorities to argue that the risk at appropriate eGFR thresholds has been substantially overestimated. However, the consequence of MALA when it occurs is severe, justifying the dose and eGFR restrictions that guide clinical use.10
Current FDA (U.S. Food and Drug Administration) and ADA (American Diabetes Association) guidance stratifies metformin use by eGFR (estimated glomerular filtration rate): metformin is contraindicated when eGFR falls below 30 mL/min/1.73m2, should be used with caution and reduced doses when eGFR is 30 to 45 mL/min/1.73m2 (with more frequent renal monitoring), and can be used at full doses when eGFR exceeds 45 mL/min/1.73m2. For patients with eGFR 45 to 60 mL/min/1.73m2, dose should not be increased above current levels and renal function should be monitored every 3 to 6 months. Before any procedure using iodinated contrast media, metformin should be held at the time of the procedure and not restarted for 48 hours, pending recheck of renal function to confirm the absence of contrast-induced nephropathy. This hold is particularly critical because acute contrast nephropathy can rapidly shift a patient from a safe to a contraindicated eGFR range while high metformin concentrations remain in tissues. Metformin should also be held perioperatively for major surgery (48 hours before and after) due to the risk of acute renal impairment from hemodynamic instability, blood loss, and nephrotoxic anesthetic or antibiotic agents during the perioperative period.12
Vitamin B12 (cobalamin) depletion is a frequently underrecognized adverse effect of long-term metformin use. Metformin reduces ileal absorption of the vitamin B12-intrinsic factor (IF) complex by interfering with calcium-dependent binding of the complex to its ileal receptor; this effect is reversible with calcium supplementation. The prevalence of vitamin B12 deficiency in metformin-treated patients is estimated at 5 to 30 percent depending on duration of use and dose, with higher rates in patients on proton pump inhibitors (PPIs) or histamine type-2 receptor antagonists (which further reduce intrinsic factor secretion). Subclinical B12 deficiency manifests first as elevated homocysteine and methylmalonic acid levels, followed by macrocytic anemia, and ultimately peripheral neuropathy that may mimic or worsen diabetic polyneuropathy and complicate clinical assessment. ADA guidelines recommend periodic monitoring of vitamin B12 levels (every 2 to 3 years) in patients on long-term metformin therapy, with B12 supplementation if deficiency is detected.11
In PCOS (polycystic ovary syndrome), metformin reduces hyperinsulinemia, lowers androgen production through suppression of ovarian and adrenal steroidogenesis, and partially restores menstrual regularity and ovulation in anovulatory PCOS patients. While letrozole has supplanted metformin as first-line therapy for ovulation induction in most patients, metformin is still used as adjunct therapy particularly in PCOS patients with impaired glucose tolerance or T2DM. In pregnancy, metformin crosses the placenta and reaches fetal concentrations comparable to maternal levels. Despite this, multiple randomized trials (including MFMU Network GDM study, MiG trial for gestational diabetes) have demonstrated no increase in major birth defects with first-trimester exposure, and metformin is used for gestational diabetes mellitus (GDM) when patient preference or insulin refusal warrants pharmacological alternatives to insulin. Long-term follow-up data (TOFU study) suggest some excess adiposity in offspring exposed to metformin in utero, an area of ongoing investigation. ADA guidelines recommend insulin as the preferred agent in pregnancy, with metformin as an acceptable alternative in GDM when patient-specific factors support its use.
The gastrointestinal adverse effects of metformin (nausea, diarrhea, abdominal cramping, bloating, metallic taste) affect approximately 20 to 30 percent of patients initiating immediate-release metformin and are the leading cause of discontinuation. These adverse effects are dose-dependent, concentration-dependent (driven by peak luminal drug concentrations), and attenuated by taking metformin with food, using gradual dose titration (e.g., starting at 500 mg once daily with dinner, increasing weekly to target dose of 1,500 to 2,000 mg daily in divided doses), and transitioning to metformin XR (extended-release) in patients who do not tolerate immediate-release despite dose titration. Persistent severe gastrointestinal intolerance despite XR formulation and optimized dose titration is a legitimate indication to discontinue metformin and select an alternative first-line agent, as forcing adherence to an intolerable regimen reduces overall treatment effectiveness through intermittent use and non-adherence.8
The 2023 ADA/EASD (American Diabetes Association/European Association for the Study of Diabetes) consensus guidelines represent a fundamental shift in T2DM (type 2 diabetes mellitus) pharmacological management: from a glucose-centric stepwise algorithm to a patient-centered framework in which comorbidity-driven agent selection takes precedence over glycemia-first dose escalation. Within this framework, metformin retains its role as the foundational first-line agent for most patients, while the agents covered in this module, sulfonylureas and meglitinides, occupy an evidence-supported but secondary role defined principally by their low cost, efficacy, and the specific contexts in which their secretagogue mechanism is clinically appropriate.
The ADA/EASD consensus framework establishes that treatment decisions for T2DM should be organized around three clinical axes: (1) established ASCVD (atherosclerotic cardiovascular disease) or high cardiovascular risk, in which GLP-1 (glucagon-like peptide-1) receptor agonists or SGLT-2 (sodium-glucose cotransporter-2) inhibitors with proven cardiovascular benefit are preferred; (2) heart failure (particularly HFrEF, heart failure with reduced ejection fraction) or CKD (chronic kidney disease), in which SGLT-2 inhibitors are preferred for their cardiorenal protective effects; and (3) need for weight management or minimization of hypoglycemia risk, in which GLP-1 receptor agonists are preferred. Sulfonylureas and meglitinides are not preferred in any of these three clinical axes but retain an important role in the fourth major category: cost-sensitive prescribing, where the low cost of generic sulfonylureas makes them the preferred option when patient financial constraints or health system resources preclude the use of GLP-1 receptor agonists or SGLT-2 inhibitors.12
Metformin is initiated at the time of T2DM diagnosis in most patients, combined with lifestyle modification. The target HbA1c is individualized based on age, comorbidities, hypoglycemia risk, and patient preferences, with less stringent targets (less than 8 percent) in older adults, patients with limited life expectancy, or those with multiple comorbidities, and tighter targets (less than 6.5 to 7 percent) in younger patients with shorter disease duration and no major comorbidities. When HbA1c remains above target after 3 months of metformin monotherapy at maximally tolerated doses, the addition of a second agent is indicated. The choice of second agent is guided by the comorbidity axes described above: in the absence of established ASCVD (atherosclerotic cardiovascular disease), HF (heart failure), or CKD (chronic kidney disease), a sulfonylurea, DPP-4 (dipeptidyl peptidase-4) inhibitor, SGLT-2 inhibitor, GLP-1 receptor agonist, or thiazolidinedione (TZD) may be added, with the choice informed by hypoglycemia risk, weight considerations, cost, and patient preference. The CAROLINA (CARdiovascular Outcome trial of LINAgliptin versus Glimepiride in T2DM) trial, comparing glimepiride with linagliptin (a DPP-4 inhibitor) as add-on to metformin, demonstrated non-inferior cardiovascular outcomes for glimepiride while confirming its superior HbA1c reduction but significantly higher hypoglycemia rates, providing a contemporary evidence basis for both the efficacy and the hypoglycemia liability of sulfonylureas in the metformin combination context.13
Early combination therapy, defined as initiating two agents simultaneously at or shortly after T2DM diagnosis rather than sequential addition, is increasingly supported by evidence. The VERIFY (Vildagliptin EfficacY in combination with metfoRmIn For earlY treatment of T2DM) trial demonstrated that early combination of metformin with a DPP-4 inhibitor sustained glycemic control for a significantly longer period before HbA1c failure compared with initial metformin monotherapy with sequential addition. The rationale is that early combination therapy addresses multiple pathophysiological defects of T2DM simultaneously, may slow beta cell functional decline by reducing glucotoxicity, and avoids the protracted period of suboptimal glycemic control that characterizes delayed sequential intensification. For patients presenting with HbA1c greater than 9 percent or greater than 2 percent above target, the ADA (American Diabetes Association) guidelines explicitly recommend initiating combination therapy rather than monotherapy, as monotherapy has a low likelihood of achieving target HbA1c in this range. Some authorities advocate extending this principle to sulfonylurea initiation alongside metformin in high-HbA1c, cost-sensitive settings to achieve rapid glycemic control, accepting the subsequent requirement for secretagogue dose reduction as glycemia improves.12
When metformin is contraindicated (eGFR below 30 mL/min/1.73m2, severe hepatic impairment, known hypersensitivity) or not tolerated despite optimized dose titration and XR formulation, the selection of an alternative first-line agent follows a modified comorbidity-driven framework. For patients with established ASCVD or high cardiovascular risk: a GLP-1 receptor agonist or SGLT-2 inhibitor is preferred regardless of glycemic level. For patients with HF or CKD: an SGLT-2 inhibitor (adjusting for the eGFR threshold for glycemic efficacy, typically above 30 for empagliflozin and dapagliflozin in HF but above 45 for glycemic effect) or a GLP-1 receptor agonist. For cost-sensitive patients without established cardiovascular indications: a sulfonylurea as monotherapy at low initial doses with careful hypoglycemia counseling. DPP-4 inhibitors are well tolerated and safe across most comorbidity contexts (with dose adjustment for renal impairment) and represent a reasonable alternative first-line option in metformin-intolerant patients without specific comorbidity-driven indications.
Drug interactions are clinically relevant for all three drug classes covered in this module. Sulfonylureas are displaced from albumin binding by NSAIDs (non-steroidal anti-inflammatory drugs), warfarin, and fibrates, transiently raising free drug concentrations and hypoglycemia risk. Fluconazole, a potent CYP2C9 (cytochrome P450 2C9) inhibitor, markedly increases sulfonylurea plasma concentrations, particularly glipizide and glimepiride which are CYP2C9 substrates; co-prescription warrants close glucose monitoring. For metformin, the key interactions are renal transporter competition: cimetidine, dolutegravir, and vandetanib inhibit OCT2 (organic cation transporter 2) and MATE (multidrug and toxin extrusion protein) transporters, reducing metformin tubular secretion and raising plasma and tissue concentrations. Trimethoprim and certain antimalarial drugs inhibit MATE transporters and can modestly increase metformin levels; this interaction is rarely clinically significant at standard doses but is relevant in patients with borderline renal function. Iodinated contrast media do not directly interact with metformin pharmacokinetically but may precipitate acute kidney injury that then causes metformin accumulation, which is the basis of the pre-contrast hold recommendation discussed in Section 4.14
The practical prescribing summary for this module is as follows. Metformin is initiated in virtually all T2DM patients without contraindications, starting at 500 mg once daily with the largest meal, increasing by 500 mg weekly to a target of 1,500 to 2,000 mg daily in divided doses; eGFR should be checked at baseline and annually thereafter. Sulfonylureas are added when cost is the primary constraint, when rapid HbA1c lowering is needed without access to more expensive agents, or when a secretagogue mechanism is specifically indicated; glipizide is preferred in CKD, glyburide is avoided in CKD. Meglitinides are reserved for patients with irregular meal schedules, CKD precluding sulfonylurea use, or prior sulfonylurea hypoglycemia in whom a prandial secretagogue remains desired. All secretagogues require patient education on hypoglycemia recognition and treatment (15 g fast-acting glucose, Rule of 15), sick-day rules (hold secretagogue during acute illness with anorexia or vomiting), and the specific dietary and behavioral factors that increase hypoglycemia risk (alcohol ingestion, delayed or skipped meals, vigorous unplanned exercise).12
Ashcroft FM, Rorsman P. K(ATP) channels and islet hormone secretion: new insights and controversies. Nat Rev Endocrinol. 2013;9(11):660–669.
doi:10.1038/nrendo.2013.166Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751–755.
doi:10.1111/j.1532-5415.1996.tb03729.xRosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–1166.
doi:10.1001/jama.2019.13772Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998;47(3):345–351.
doi:10.2337/diabetes.47.3.345Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174.
doi:10.1172/JCI13505Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355–2369.
doi:10.1172/JCI40671Duca FA, Cote CD, Rasmussen BA, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med. 2015;21(5):506–511.
doi:10.1038/nm.3787Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.
doi:10.2165/11534750-000000000-00000UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
doi:10.1016/S0140-6736(98)07037-8Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967.
doi:10.1002/14651858.CD002967.pub4de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.
doi:10.1136/bmj.c2181American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
doi:10.2337/dc24-SINTRosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–1166.
doi:10.1001/jama.2019.13772Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–2675.
doi:10.1001/jama.2014.15298Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
doi:10.1056/NEJMoa0806470